Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:37 PM
Ignite Modification Date:
2025-12-24 @ 5:37 PM
NCT ID:
NCT02142868
Eligibility Criteria:
Inclusion Criteria:
* Post-menopausal women 18 years of age or above with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)
* ER-positive and/or PR-positive tumor based on local laboratory results
* HER2-negative tumor based on local laboratory results
* Patients must be appropriate candidates for letrozole therapy (Canada: first-line patients only)
Exclusion Criteria:
* Patients who have previously participated in a palbociclib trial or who have received prior treatment with any CDK inhibitor
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT02142868
Study Brief:
Protocol Section:
NCT02142868